Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for G&E Herbal Biotechnology Co., Ltd. (4911:TWSE), powered by AI.
G&E Herbal Biotechnology Co., Ltd. is currently trading at $31.40. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for G&E Herbal Biotechnology Co., Ltd. on Alpha Lenz.
View G&E Herbal Biotechnology Co., Ltd.'s valuation metrics on Alpha Lenz.
“G&E Herbal Biotechnology Co., Ltd.'s ROE is 15.8%. Explore profitability and growth together.”
Ask for details →G&E Herbal Biotechnology Co., Ltd. is a biotechnology company specializing in the development, manufacture, and commercialization of novel botanical drugs, western and herbal medicines, and biotechnological services. Founded in 2002 and headquartered in Tainan, Taiwan, the company operates within the health technology sector, with a particular focus on pharmaceuticals and botanical extraction technologies. Its product portfolio includes hepatic protective agents, botanical anti-aging cosmetics, healthcare supplements, topical gels, and lubricants, serving the health and personal care needs of a diverse customer base. G&E Herbal Biotechnology is notable for integrating proprietary botanical extraction processes with clinical research, including ongoing trials for potential treatments targeting conditions such as liver and prostate diseases, and various cancers. By controlling the full supply chain—from contracted cultivation of plant materials to regulated processing—the company ensures traceability and quality in its botanical offerings. With a lean team of approximately 39 employees, G&E Herbal Biotechnology holds a respected position in Taiwan’s life sciences sector, contributing to the advancement of plant-based healthcare and pharmaceutical innovation.
“G&E Herbal Biotechnology Co., Ltd.'s ROE is 15.8%. Explore profitability and growth together.”
Ask for details →G&E Herbal Biotechnology Co., Ltd. (ticker: 4911) is a company listed on TWSE in the Healthcare sector (Biotechnology). It has approximately 39 employees.
The current price is 31.4 with a P/E ratio of -x and P/B of -x.
ROE is 15.80% and operating margin is 49.27%. Annual revenue is $309M.